Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan pharmacokinetics in paediatric allogeneic HSCT
2013-003257-20Phase 4Completed
- Sponsor
- Great Ormond Street Hospital
- Start
- Mar 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of treosulfan in leukemia, Immunogenetic disorder, Congenital Metabolic Diseases and 2 more, sponsored by Great Ormond Street Hospital. Primary endpoints: Treosulfan Cmax, Treosulfan half-life (t1/2) and 1 more. Started Mar 2014; status: completed.
02
Drugs
treosulfan
03
Conditions
leukemiaImmunogenetic disorderCongenital Metabolic Diseasesautoimmune diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2013-003257-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003257-20.